A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

Running, not enrolling · Phase 1

Conditions studied: Neuroblastoma

In brief

The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.

Key facts

Study ID

NCT04106219

Run by

Eli Lilly and Company

People needed

71

Starts

2020-06-11

Expected to finish

2026-08-01

Last updated by the study team

2026-04-21

Who can join

Age: 2 and older, up to 21. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must have relapsed/refractory neuroblastoma and have active disease in at least one site: bone, bone marrow or soft tissue. Participants must be able to submit an archival sample of tissue.
• Participants must be able to swallow capsules.

You may not qualify if…

• Participants must not have had an allogeneic hematopoietic stem cell, bone marrow, or solid organ transplant.
• Participants must not have untreated tumor that has spread to the brain or spinal cord.
• Participants must not have a serious active disease other than neuroblastoma.
• Participants must not have a condition affecting absorption.
• Participants must not have had prior aurora kinase inhibitor exposure.
• Participants must not have a known allergy to the study treatment.
• Participants must not have symptomatic human immunodeficiency virus (HIV) infection or symptomatic activated/reactivated hepatitis A, B, or C.

Where it is running

• UCSF Medical Center at Mission Bay — San Francisco, California, United States
• Children's Hospital Colorado — Aurora, Colorado, United States
• University of Chicago - Comer Children's Hospital — Chicago, Illinois, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• Cincinnati Childrens Hospital Medical Center — Cincinnati, Ohio, United States
• Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
• Texas Childrens Hospital — Houston, Texas, United States
• Perth Children's Hospital — Perth, Western Australia, Australia
• UZ Gent — Ghent, Oost-Vlaanderen, Belgium
• Centre Leon Berard — Lyon, Auvergne-Rhône-Alpes, France
• Institut Curie — Paris, France
• Universitätsklinikum Köln — Cologne, Germany
• Istituto Nazionale dei Tumori — Milan, Lombardy, Italy
• National Cancer Center Hospital — Chuo-ku, Tokyo, Japan
• Hospital Universitari Vall d'Hebron — Barcelona, Barcelona [Barcelona], Spain
• Hospital Infantil Universitario Niño Jesús — Madrid, Spain
• Alder Hey Children's Hospital — Liverpool, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.